These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26682241)

  • 1. Actionability and precision oncology.
    Schwaederle M; Kurzrock R
    Oncoscience; 2015; 2(10):779-80. PubMed ID: 26682241
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality.
    Tarantino P; Mazzarella L; Marra A; Trapani D; Curigliano G
    Cancer Treat Rev; 2021 Mar; 94():102169. PubMed ID: 33652262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants.
    Li X; Warner JL
    Front Cell Dev Biol; 2020; 8():48. PubMed ID: 32117976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
    Trapani D; Crimini E; Sandoval J; Curigliano G
    Cancer Treat Res; 2023; 188():343-351. PubMed ID: 38175352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
    Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
    Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actionable data for precision oncology: Framing trustworthy evidence for exploratory research and clinical diagnostics.
    Tempini N; Leonelli S
    Soc Sci Med; 2021 Mar; 272():113760. PubMed ID: 33601250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
    Suehnholz SP; Nissan MH; Zhang H; Kundra R; Nandakumar S; Lu C; Carrero S; Dhaneshwar A; Fernandez N; Xu BW; Arcila ME; Zehir A; Syed A; Brannon AR; Rudolph JE; Paraiso E; Sabbatini PJ; Levine RL; Dogan A; Gao J; Ladanyi M; Drilon A; Berger MF; Solit DB; Schultz N; Chakravarty D
    Cancer Discov; 2024 Jan; 14(1):49-65. PubMed ID: 37849038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
    Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
    JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices.
    Ersek JL; Black LJ; Thompson MA; Kim ES
    Am Soc Clin Oncol Educ Book; 2018 May; 38():188-196. PubMed ID: 30231363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's in Between the Lines: Assessing the Readability, Understandability, and Actionability in Breast Cancer Survivorship Print Materials.
    Parker PD; Prabhu AV; Su LJ; Zorn KK; Greene CJ; Hadden KB; McSweeney JC
    J Cancer Educ; 2022 Oct; 37(5):1532-1539. PubMed ID: 33822316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
    Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
    Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics.
    Arga KY; Attia H; Aziz RK
    OMICS; 2024 Jan; 28(1):5-7. PubMed ID: 38190279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program.
    Katsoulakis E; Duffy JE; Hintze B; Spector NL; Kelley MJ
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.
    Horak P; Leichsenring J; Goldschmid H; Kreutzfeldt S; Kazdal D; Teleanu V; Endris V; Gieldon L; Allgäuer M; Volckmar AL; Dikow N; Renner M; Kirchner M; Penzel R; Ploeger C; Brandt R; Seker-Cin H; Budczies J; Heilig CE; Neumann O; Schaaf CP; Schirmacher P; Fröhling S; Stenzinger A
    Genes Chromosomes Cancer; 2022 Jun; 61(6):303-313. PubMed ID: 34331337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward Precision Oncology in Glioblastoma with a Personalized Cancer Genome Reporting Tool and Genetic Changes Identified by Whole Exome Sequencing.
    Erdogan O; Özkaya ŞÇ; Erzik C; Bilguvar K; Arga KY; Bayraklı F
    OMICS; 2023 Sep; 27(9):426-433. PubMed ID: 37669106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of population-level pharmacogenetic actionability in Alabama.
    Davis BH; Williams K; Absher D; Korf B; Limdi NA
    Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring Progress in Precision Oncology.
    Horak P; Fröhling S
    Cancer Discov; 2024 Jan; 14(1):18-19. PubMed ID: 38213297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
    Sadik H; Pritchard D; Keeling DM; Policht F; Riccelli P; Stone G; Finkel K; Schreier J; Munksted S
    JCO Precis Oncol; 2022 Oct; 6():e2200246. PubMed ID: 36315914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.